COMMUNIQUÉS West-GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/07/2026
RESEARCH TRIANGLE PARK, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired [...]
VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program
02/07/2026
ATUM, a leading US-based contract research organization, selected to support stable clonal cell line generation to advance VERAXA’s lead BiTAC-TCE program toward IND/CTA-enabling activities ZURICH, SWITZERLAND – July 02 [...]
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/07/2026
NEW HAVEN, Conn., July 02, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on July 1, 2026, Invivyd granted 14 newly hired non-executive employees options to purchase an aggregate of 493,000 [...]
Cartesian Therapeutics Announces New Employment Inducement Grants
02/07/2026
FREDERICK, Md., July 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced [...]
Burning Rock Announces Founder’s Purchase of Its ADSs
02/07/2026
GUANGZHOU, China, July 02, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in [...]
Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM
02/07/2026
- Acoramidis initiation was associated with rapid kidney-protective activity as exhibited in a hemodynamically mediated, reversible eGFR dip and a placebo-corrected 15.5% reduction in UACR by Day 28 (P<0.05), with no [...]
Polyrizon Announces Successful Results for NASARIX™ Biocompatibility Program, Supporting Advancement Towards First in Human Clinical Trial
02/07/2026
Raanana, Israel, July 02, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, [...]
Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention
02/07/2026
New Taipei City, Taiwan, July 02, 2026 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization [...]
Cannara obtient les droits exclusifs au Canada sur la technologie d’infusion Ampersand™ Live Rosin de Blue River
02/07/2026
Ce partenariat associe le leadership de Cannara dans le domaine du cannabis haut de gamme sans solvant à la technologie d’infusion exclusive de Blue River afin de proposer une nouvelle génération de produits à base de [...]
Cannara Secures Exclusive Canadian Rights to Blue River's Ampersand™ Live Rosin Infusion Technology
02/07/2026
Partnership combines Cannara's leadership in premium solventless cannabis with Blue River's proprietary infusion technology to bring a new generation of live rosin products to Canadian consumers MONTREAL, July 02, 2026 [...]
Kane Biotech Announces Results of Annual and Special Meeting of Shareholders
02/07/2026
WINNIPEG, Manitoba, July 02, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) the voting results from its annual and special meeting of shareholders (the “Meeting”) on [...]
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
02/07/2026
ZUG, Switzerland, July 02, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and [...]
The Ensign Group Purchases Real Estate and Operations in Texas
02/07/2026
SAN JUAN CAPISTRANO, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
Treos Bio Presents New Translational Data Showing PolyPEPI1018 Plus Anti-PD-L1 Immunotherapy Remodels the Tumor Immune Microenvironment in MSS Colorectal Cancer
02/07/2026
ESMO GI poster highlights increased intratumoral CD8+ T-cell infiltration, PD-L1 expression, expansion of tumor-reactive TCR clonotypes and association with clinical outcome LONDON and BOSTON and BUDAPEST, Hungary, July [...]
HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification
02/07/2026
First selective MET inhibitor approved for patients with MET-amplified advanced gastric cancer or gastroesophageal junction adenocarcinoma in China HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 02, 2026 (GLOBE [...]
Xeltis exceeds 50% enrollment in US Pivotal trial for aXess™, its vascular access device for hemodialysis
02/07/2026
US pivotal trial is a multi-center study evaluating a bioabsorbable hemodialysis vascular access implant across complex hemodialysis patients representing real-world practice > 50% of target enrollment reached across [...]
Anaveon Appoints Laetitia Pouzol as Chief Scientific Officer
02/07/2026
BASEL, Switzerland, July 02, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage biotechnology company pioneering precision biologics to reprogram the immune system for the treatment of autoimmune and inflammatory diseases, [...]
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
02/07/2026
ZUG, Switzerland, July 2, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with [...]
Abivax annonce l’exercice intégral de l’option de souscription d’ADS supplémentaires des teneurs de livre associés, portant le produit brut de l’Offre à 920 M$ (807 M€)
02/07/2026
Abivax annonce l’exercice intégral de l’option de souscription d’ADS supplémentaires des teneurs de livre associés, portant le produit brut de l’Offre à 920 M$ (807 M€) PARIS, France, 2 juillet 2026 – 08h00 CEST – [...]

Pages